Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients

This study has been completed.
Sponsor:
Information provided by:
Avanir Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00050232
First received: December 2, 2002
Last updated: May 5, 2014
Last verified: May 2014